Interferon for hepatitis C patients with psychiatric disorders.
Asnis
Gregory M
GM
De La Garza
Richard
R
Rego
Simon A
SA
Henderson
Margaret A
MA
Reinus
John F
JF
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000139:chemically induced; D015897:Comorbidity; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D001523:Mental Disorders / Q000453:epidemiology*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000209:etiology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a